Carisma Therapeutics, Inc.

CARM

US14216R1014

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
1.41 ^USD	-0.70%		+0.71%	-51.88%

05-16	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte	CI
05-09	Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Eleven Biotherapeutics, Inc. has Changed its Name to Sesen Bio, Inc

May 16, 2018 at 05:00 am

On May 16, 2018, Eleven Biotherapeutics, Inc. changed its name to Sesen Bio, Inc.

Latest news about Carisma Therapeutics, Inc.

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte	05-16	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer	05-02	CI
BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	04-11	MT
HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	04-02	MT
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline	04-01	MT
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-01	CI
Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors	04-01	CI
North American Morning Briefing : Stock Futures -2-	03-19	DJ
North American Morning Briefing : Inflation Data -2-	03-12	DJ
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment	12-14	MT
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy	11-28	MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte	11-28	CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
North American Morning Briefing : Stocks Look to -2-	11-06	DJ
Carisma Therapeutics Inc. Presents Pre-Clinical Proof of Concept for in vivo CAR-M Using mRNA Platform in Collaboration with Moderna at SITC	31/10/23	CI
Carisma Therapeutics Inc. to Present First Results from in Vivo Car-M Collaboration with Moderna at SITC 2023	25/10/23	CI
Capital Starts Carisma Therapeutics at Overweight With $10 Price Target	03/10/23	MT
Carisma Therapeutics, Inc. Announces Latest Data from Phase 1 Clinical Trial of CT-0508 At 8th Annual CAR-TCR Summit	01/09/23	CI
HC Wainwright Adjusts Price Target on CARISMA Therapeutics to $11 From $10, Keeps Buy Rating	11/08/23	MT
North American Morning Briefing : Investors Await -2-	07/08/23	DJ
Evercore ISI Initiates CARISMA Therapeutics at Outperform With $12 Price Target	06/07/23	MT
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with Keytruda(R) (Pembrolizumab) in Patients with Her2 Overexpressing Solid Tumors	28/06/23	CI
Carisma Therapeutics Inc. Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources	14/06/23	CI

Chart Carisma Therapeutics, Inc.

Duration

Period

More charts

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No:TPS2682

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Carisma Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.41 USD

Average target price

7.6 USD

Spread / Average Target

+439.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CARISMA THERAPEUTICS, INC.	-51.88%	58.58M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.76%	21.97B
GENMAB A/S	-4.78%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs

Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Eleven Biotherapeutics, Inc. has Changed its Name to Sesen Bio, Inc

Latest news about Carisma Therapeutics, Inc.

Chart Carisma Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Carisma Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs